Jami Fukui to Humans
This is a "connection" page, showing publications Jami Fukui has written about Humans.
Connection Strength
0.299
-
Lee HH, Siu-Li N, Pagano I, Fukui JA. Examining a Genomic Test in Predicting Extended Endocrine Benefit and Recurrence Risk in a Diverse Breast Cancer Population. Curr Oncol. 2025 Sep 25; 32(10).
Score: 0.042
-
Xia K, Chen E, Hu R, Pagano I, Fukui J. Applicability of Oncotype DX Testing in a Diverse Breast Cancer Population in Hawaii. Breast J. 2025; 2025:9104103.
Score: 0.042
-
Hamachi A, Matriz J, Fukui J. The use of complementary and alternative medicine among cancer patients in Hawaii. BMC Complement Med Ther. 2025 May 08; 25(1):167.
Score: 0.041
-
Bansil S, Silva A, Taniguchi A, Wiedmer C, Fernandez M, Pagano I, Vierkoetter K, Killeen J, Fukui J. Racial/Ethnic Differences Among Tumor-Infiltrating Lymphocytes in Breast Cancer Tumors. Oncologist. 2023 02 08; 28(2):116-122.
Score: 0.035
-
Cheng S, Nguyen ET, Pagano I, Fukui JA. Genomic Landscape of Circulating-Tumor DNA in a Diverse Cohort of Metastatic Breast Cancer Patients. Oncol Res Treat. 2023; 46(1-2):26-32.
Score: 0.035
-
Fukui J, White K, Frankland TB, Oshiro C, Wilkens L. Weight changes according to treatment in a diverse cohort of breast cancer patients. BMC Cancer. 2021 Sep 08; 21(1):1005.
Score: 0.032
-
Abe JV, Fukui J, Wilkens LR, Cheng I, Wu AH, Hernandez BY, Loo LWM. Risk factors for ductal carcinoma in situ: comparisons with invasive breast cancer. Breast Cancer Res. 2026 Apr 01; 28(1).
Score: 0.011
-
Fujii T, Iwase T, Shen Y, Fukui J, Ueno NT. Reconsidering the definition of triple-negative breast cancer in the immune checkpoint inhibitor era: an optimal cut-off value for hormone receptor percentage of HER2-negative invasive breast cancer. Br J Cancer. 2026 Jan; 134(1):1-7.
Score: 0.011
-
Patel R, Fukui J, Klein P, Moshier E, Kocyigit H, Fiedler L, Bucwinska W, Xing XY, Shapiro C, Goel A, Fasano J, Shao T, Bhardwaj A, Kim E, Vaccaro R, Lee K, Wilck E, Tiersten A. Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer. Breast Cancer Res Treat. 2025 Nov; 214(2):159-170.
Score: 0.010
-
Lewis FM, Ganschow P, Manst D, Derry-Vick H, Tercyak KP, Griffith KA, Oxford M, Fukui J, Gadi VK, Phillips F. Behavioral-Emotional Functioning of Children of Parents with Early Compared to Advanced Cancer. J Palliat Med. 2025 Jun; 28(6):724-731.
Score: 0.010
-
Taparra K, Fukui J, Killeen J, Sumida K, Loo LWM, Hernandez BY. Racial and Ethnic Disparities in Rates of Invasive Second Breast Cancer Among Women With Ductal Carcinoma In Situ in Hawai'i. JAMA Netw Open. 2021 10 01; 4(10):e2128977.
Score: 0.008
-
Arnobit CI, Loo K, Pagano I, Uchiyama M, Fukui J, Braun-Inglis C, Bantum EO. Recruiting Cancer Survivors to a Mobile Mindfulness Intervention in the United States: Exploring Online and Face-to-Face Recruitment Strategies. Int J Environ Res Public Health. 2021 09 27; 18(19).
Score: 0.008
-
Meno M, Abe J, Fukui J, Braun-Inglis C, Pagano I, Acoba J. Telehealth amid the COVID-19 pandemic: perception among Asian, Native Hawaiian and Pacific Islander cancer patients. Future Oncol. 2021 Aug; 17(23):3077-3085.
Score: 0.008
-
Kadariya Y, Tang B, Myers CB, Fukui J, Peterson JR, Kruger WD. Chemical genetic screening for compounds that preferentially inhibit growth of methylthioadenosine phosphorylase (MTAP)-deficient Saccharomyces cerevisiae. J Biomol Screen. 2011 Jan; 16(1):44-52.
Score: 0.004
-
Gauvin TJ, Fukui J, Peterson JR, Higgs HN. Isoform-selective chemical inhibition of mDia-mediated actin assembly. Biochemistry. 2009 Oct 13; 48(40):9327-9.
Score: 0.003